Company intelligence / Profile preview

SymBio Services

Minato-ku, Tokyo, Japan

Ownership: Private
Development stage: Other

Overview

SymBio Pharmaceuticals is a Japanese specialty pharmaceutical company focused on the development and commercialization of new drug candidates, particularly for oncology and infectious diseases. Its lead product, brincidofovir, is approved in Japan for certain viral infections. The company also has clinical-stage assets targeting hematological cancers.

Therapeutic areas: HematologyOncologyInfectious Diseases
Modalities: Small moleculeBiologic
Industry: Biotech

Partnerships

Onconova Therapeutics (historically)

Beyond the preview

Go deeper on SymBio Services.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on SymBio Services.

Explore the full profile